Table 4 Clinical situations where the cure probability was >26% (75th percentile).

From: ‘Potentially curative therapies’ for hepatocellular carcinoma: how many patients can actually be cured?

Clinical features

Cure prob. (95% C.I.)

Years of life lost (95% C.I.)

Gender

Hepatitis C

Tumour burden

ALBI

All patients

Age < 60 years

Age 60–70 years

Age > 70 years

Female

Negative

Single <2 cm

1

39.8% (31.3, 48.3)

19.5 (18.0, 21.1)

13.0 (11.4, 14.5)

6.5 (5.0, 8.0)

Female

Negative

Single 2–3 cm

1

35.7% (27.2, 44.3)

20.3 (18.7, 21.8)

13.7 (12.2, 15.2)

7.2 (5.7, 8.7)

Male

Negative

Single <2 cm

1

33.8% (25.3, 42.4)

17.8 (16.2, 19.3)

11.2 (9.7, 12.8)

4.7 (3.2, 6.2)

Female

Positive

Single <2 cm

1

32.3% (24.0, 40.9)

21.0 (19.5, 22.6)

14.5 (13.0, 16.0)

8.0 (6.4, 9.5)

Female

Negative

Single <2 cm

2

32.1% (23.8, 40.7)

21.3 (19.7, 22.8)

14.8 (13.2, 16.3)

8.2 (6.7, 9.7)

Male

Negative

Single 2–3 cm

1

29.6% (21.5, 38.2)

18.5 (17.0, 20.0)

12.0 (10.4, 13.5)

5.4 (3.9, 6.9)

Female

Negative

2-3 nodules <2 cm

1

28.9% (20.8, 37.4)

21.3 (19.7, 22.8)

14.7 (13.2, 16.3)

8.3 (6.7, 9.7)

Female

Positive

Single 2–3 cm

1

28.1% (20.2, 36.7)

21.7 (20.2, 23.3)

15.2 (13.7, 16.7)

8.7 (7.1, 10.2)

Male

Positive

Single <2 cm

1

26.3% (18.5, 34.8)

19.3 (17.7, 20.8)

12.7 (11.2, 14.2)

6.2 (4.7, 7.7)

  1. Estimates consider that clinical features not included were at their mean and that patients were treated from 2014 onward.
Back to article page